GlassScriptPhysician profile
Melissa D Carter
NPI 1629508767
$5,257.29
in general payments reported to CMS, 2019-2025
34 companies · $1,243 in 2025
The $1,243 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $187 · 2022: $1,062 · 2023: $1,234 · 2024: $1,531 · 2025: $1,243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,008.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,254.43 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $837.02 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $609.63 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $332.39 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $316.23 | 2022-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $254.58 | 2022-2025 | |
| Shield Therapeutics INC | $206.12 | 2023-2025 | Accrufer |
| Amgen INC. | $203.73 | 2022-2025 | Evenity, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $203.49 | 2023-2025 | |
| Exact Sciences Corporation | $107.23 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.56 | 2021-2023 | Xifaxan |
| Viatris Specialty LLC | $75.48 | 2025 | Yupelri |
| Novartis Pharmaceuticals Corporation | $62.91 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.14 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $61.72 | 2022-2024 | Steglatro, Belsomra, Gardasil 9 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $56.07 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Renalytix Ai, INC. | $51.54 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Astellas Pharma US INC | $47.78 | 2022-2024 | Veozah |
| Axsome Therapeutics, INC. | $40.38 | 2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $38.73 | 2022 | |
| Phathom Pharmaceuticals, INC. | $38.35 | 2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.30 | 2025 | Caplyta |
| Ardelyx, INC. | $37.79 | 2023 | Ibsrela |
| Idorsia Pharmaceuticals US INC | $35.43 | 2022-2023 | Quviviq |
| Dexcom, INC. | $35.36 | 2024-2025 | Dexcom G6 Transmitter |
| Alkermes, INC. | $24.81 | 2024 | Vivitrol |
| Otsuka America Pharmaceutical, INC. | $20.45 | 2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $20.35 | 2022 | |
| Bausch Health US, LLC | $19.07 | 2022 | |
| Sanofi-Aventis U.S. LLC | $17.25 | 2022 | |
| Sanofi Pasteur INC. | $16.57 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $15.70 | 2025 | Uzedy |
| Biohaven Pharmaceutical Holding Company LTD. | $14.08 | 2022 | |
| Sumitomo Pharma America, INC. | $12.62 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.